Idera Pharmaceuticals Inc. (NASDAQ:IDRA) on Mar. 28 announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) shares after opening at $4.05 moved to $4.07 on last trade day and at the end of the day closed at $3.71. Company price to sales ratio in past twelve months was calculated as 6501.18 and price to cash ratio as 7.90. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) showed a negative weekly performance of -18.82%.
CytRx Corporation (NASDAQ:CYTR) on Apr. 2 said that positive preclinical results from an in vivo study of aldoxorubicin in an animal model of glioblastoma will be presented at the American Association for Cancer Research Annual Meeting being held April 5-9, 2014 in San Diego CytRx Corporation (NASDAQ:CYTR) shares fell -7.85% in last trading session and ended the day on $3.64. CYTR return on equity ratio is recorded as -287.90% and its return on assets is -146.40%. CytRx Corporation (NASDAQ:CYTR) yearly performance is 38.40%.
On March 20, 2014, Sangamo BioSciences, Inc. (NASDAQ:SGMO) entered into an underwriting agreement with J.P. Morgan Securities LLC as the representative of the several underwriters named therein (the “Underwriters”), which provides for the issuance and sale in an underwritten public offering (the “Offering”) by the Company and the purchase by the Underwriters of 4,444,444 shares of common stock of the Company (the “Common Stock”). Sangamo Biosciences, Inc. (NASDAQ:SGMO) shares moved down -7.70% in last trading session and was closed at $15.46, while trading in range of $15.15 – $17.10. Sangamo Biosciences, Inc. (NASDAQ:SGMO) year to date (YTD) performance is 11.30%.
Novavax, Inc. (NASDAQ:NVAX), a clinical-stage vaccine company, announced on 2 April that Stanley C. Erck, President and Chief Executive Officer, will present at the 13th Annual Needham Healthcare Conference on April 9, 2014 at 12:10 pm ET in New York City at the Westin Grand Central Hotel. Novavax, Inc. (NASDAQ:NVAX) weekly performance is -3.54%. On last trading day company shares ended up $4.09. Novavax, Inc. (NASDAQ:NVAX) distance from 50-day simple moving average (SMA50) is -25.69%. Analysts mean target price for the company is $11.20.
Leave a Reply